On the one hand, an exclusive examination of our siRNA studies against PDGFRβ would have resulted in the findings that PDGFRβ plays a minor role in CRC and that targeting this RTK will not lead to an improvement of therapy options for patients. This evidence concerns the gene PDGFRB and colorectal carcinoma.